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1. Introduction
Chronic obstructive pulmonary disease (COPD) is 
a respiratory disorder that negatively affects lung 
function [1], deteriorates quality of life and dis-
ables patients to perform their daily duties [2]. It is 
intercalated by exacerbations, acutely worsening 
periods, which may require hospital care [1]. The 
more exacerbations a patient has, the faster their 
status drops [3]. 
By 2020, COPD will be the third most common 
death cause all over the world [4], which poses a 
severe burden on societies [1]. At the community 
level, it is our common interest to help patients 
with this condition, to foster smoking cessation 
and support their disease management [5]. On top 
of the effects on the quality of life of the patient, 
COPD results in a higher rate of utilisation of 
health services, such as medication, prolonged 
hospital stay due to exacerbations, as well as the 
subsequent need of rehabilitation. 
Current research trends in COPD disease 
management indicate that our knowledge of the 
community pharmacy setting is growing [6, 7], 
though still not abundant [2, 8]. As of Hungary, 
we have been unable to identify significant body 
of research related to COPD patient education in 
the community pharmacy setting. 1 Some examples 
of education in pulmonology centres have been 
found. These circumstances drive to our attention 
to an interesting, yet less studied area, for which 
we have implemented a pilot project in collabora-
tion with the Inczeffy Pharmacy and Medical 
Centre in Göd. 
2. Objectives
1. The primary objective was to assess the oppor-
tunities of COPD disease management in the 
community pharmacy in a pilot setting by in-
depth interviews with current COPD patients 
who are also future subjects of the education 
programme. 
1 Our Pubmed based advanced search (COPD AND Hungary 
AND patient education), also checking all relevant articles 
about (COPD AND Hungary), has not revealed any publica-
tion on community pharmacy based education of Hungarian 
COPD patients (performed by one reviewer, 31 Aug 2019).
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2. The secondary objective was to understand pa-
tient attitudes, perceptions, fears, beliefs that af-
fect the everyday life of patients. This is highly 
valuable input to the education programme, be-
cause it sets the guidelines for the educational 
content, whilst providing major insights into 
how patients relate to their disease. 
3. The tertiary objective was to create a local good 
practice and to investigate how the community 
pharmacy pillar of integrated care can work in 
the context of a small town in Hungary. 
3. Methods
3.1. Study context
Göd is a medium-size city with around 19,800 in-
habitants [9]. According to the Rotterdam Study [5], 
COPD prevalence on an overall basis is 4.6%, so 5% 
seems to be a rationale approximation in a European 
setting [4]. This means that the overall COPD popu-
lation of Göd should be around 95 people, out of 
which, N=6 were included in our study (7%). Inczef-
fy Pharmacy is a central and well-known communi-
ty pharmacy in the city, and it has gained an innova-
tive reputation due to their previous commitment in 
previous patient education programmes. 
This explorative study joins methodologically a 
series of studies. Besides patient interviews in the 
pharmacy and the pulmonology outpatient cen-
tres, pulmonologist expert opinion was assessed 
to develop an education programme for the COPD 
patients. Later on n=118 patients were provided 
education, and their quality of life and adherence 
changes were monitored in a longitudinal study 
with follow-up. The in-depth interview methodol-
ogy, applied in this context, helped us explore the 
opportunities of patient education in the pharma-
cy, and also to lay more stress on the pulmonolo-
gy centre pillar. 
3.2. Inclusion of study participants
During dispensing medication, patients with the 
J44 ICD classification code were offered to partic-
ipate in the pilot project. Altogether, patients 
were screened for 5 working days, 25 showed 
their interest, and 8 were willing to participate in 
the education session, and finally 6 patients 
showed up.
3.3. Interview methodology
We have performed exploratory in-depth inter-
views with the patients [10]. The structure of the 
interview has been designed to determine the key 
elements of a patient education programme; and 
to let them discover perception and therapeutic at-
titudes [11]. Table I provides an overview of this 
structure and an insight into the explorative ques-
tions. One interview lasted ca. 30 minutes. The 
methodology showed some mixed features with a 
loose semi-structured interview, since we primar-
ily set the major topics we wanted to direct pa-
Table I Interview methodology guide corresponding to the objectives of the study
Objective Topic Sample questions
1 In-depth interviews to understand patient attitudes, 
perceptions
How do you feel about your disease?
What disturbs you most in COPD?
What would you like to do if you could 
breathe freely?
Do you think your condition will get any 
better?
What does a regular day of yours look like?
2 Explorative interviews for educational content & 
insights to adherence
Do you have any questions related to your 
condition? / What would you like to know 
about it?
What have you heard about it?
Can you tell us how to use these inhalers?
What would you like to change about the 
condition?
Do you believe that you / the doctor / your 
educator can make a change? How?
3 Creating local good practice in Göd How can the pharmacy staff be engaged?
How can we engage local stakeholders to 
keep up with the project?
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tients to. Altogether, interviewed them by using 
the active listening technique, which means that 
we concentrated on their thoughts and let them 
relatively freely talk about their condition. At the 
end of the interviews, patients participated in an 
educational session (prototype education) where 
they could ask freely about their doubts related to 
their disease. Their reactions were assessed before 
and after the prototype session.
3.4. Symptom assessment
We invited the patients to self-administer the 
COPD Assessment Tool (CAT),2 which is a stan-
dard method to assess symptomatology in pulm-
onology practice [12]. CAT is an 8-item question-
naire to assess their symptoms on an ascending 
scale until 5, and scores range 0-40.  Patients are 
considered symptomatic above 10 scores.
4. Results
The community pharmacy setting is a challenging 
venue for patient education. Originally, we intend-
ed to incorporate a comparative aspect to a longi-
tudinal study which assesses the impact of educa-
tion on quality of life and adherence; however, 
pharmacy patients turned out to be more willing 
to be educated in a one-time occasion than in a fol-
low-up intervention. Consequently, the communi-
ty pharmacy pillar to this study was halted, whilst 
the interviews provided patient insight to the edu-
cation content we developed for the further course 
of the aforementioned study. The patients’ desire 
to get pharmacist advice fast [2], seems to also ap-
pear in a German setting, which verifies the need 
for pharmacy disease management projects (pa-
tients who attended such sessions were enabled to 
use their inhaler significantly better, although this 
means 29% overall) [13]. This idea has been further 
developed in Japan, where pharmacist-led clinics 
were proven to improve quality of life [14]. 
4.1. In-depth interviews to understand patient 
attitudes, perceptions 
Patients did not mention the textbook like symp-
toms (sputum secretion, dyspnoea and coughing) 
on the first instance; however, they always relate 
to real-life actions they would like to perform: to 
2 We fully complied with the guidelines at https://www.cate-
stonline.org, and we solely used the licence for academic re-
search purposes.
play tennis, to play with the grandchildren and to 
paint. Falsely, they identify their illness as asthma, 
and they see no relation to smoking (but one pa-
tient). They get used to the symptoms, and they 
mostly perceive them as “they come by age”, “they 
are natural”; thus, they accept their conditions. 
These activities should be used when developing 
the patient profile for the education content; addi-
tionally, we should use the patients’ own words to 
help them memorise its content. Figure 1 sum-
marises the results for the education content.
4.2. Educational content and insight to adherence
None of the patients was able to identify the re-
liever drug; even the most asymptomatic patient 
used it every morning, in an inadequate dose. 
Once-daily inhalers were preferred, since one oc-
casion is the frequency everyone declared as ade-
quate for the treatment of the disease. One patient 
reported a willingness to apply alternative meth-
ods, namely she was interested in herbal drinks as 
a possible treatment option. The patients were un-
aware of the inhalation therapy they used; hence, 
there was no apparent fear of steroids. Based on 
their CAT scores, all patients were symptomatic, 
which implies that they are either not compliant, 
or do not have the right medication. 
The interviews reveal a truly diverse image of 
COPD attitudes. The main symptoms are feeling 
powerless and the lack of physical performance. 
Two patients mentioned repeatedly their disability 
in moving and taking the stairs, and one patient 
was completely confined to oxygen therapy. 
The lack of adherence is a variant which was chal-
lenging to get the patient talk about. Finally, they all 
confessed that they either do not take their medica-
tion in the prescribed manner, or make changes to 
treatment regimens upon self-judgement. The better 
they feel, the less they take the medication. 
4.3. A local good practice
Since the project was well-accepted, a local epito-
me has been created in the Inczeffy Pharmacy. It is 
our ambition to keep this project going, and in or-
der to maximize the impact our our research, in-
terested pharmacies are invited to collaborate 
throughout Hungary. 
Our results are in line with review articles in 
COPD patient education in the community phar-
macy setting [15, 16]. The primary roles of the 
pharmacist should be to assess the current symp-
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toms and improving smoking habits, inhaler tech-
nique, dosage and medication use, and the provi-
sion of materials to support these activities. Based 
on the input provided by this study, we can state 
that the education materials created reflect inter-
national good practice.
5. Discussion
While designing the education content, I identi-
fied similar body of research which describes an 
educational project with n = 62 patients with mod-
erate to mild COPD (<70 years of age), who partici-
pated 2x2 hour weekly session, with 1 week gap 
fashion [17]. Education was performed through a 
19-page booklet with information on self-assess-
ment and disease management. Oral sessions in-
cluded education on the respiratory obstruction, 
anti-obstructive medication, exacerbation preven-
tion, self-assessment and self-management, and 
physiotherapy. This is a definite similarity with 
our research, since the major elements of the edu-
cation are overlapping. In line with our results, 
the implication of this is that we should make sure 
that patients understand that COPD is a chronic 
condition, and medications should be taken; also 
in case they feel right. Interestingly, SMART dos-
age is available in the case of certain drugs, so this 
is another aspect that should be included in the 
education content.
Asking the patient and the caregiver at the 
same time can draw our attention to new discov-
eries [18]. For the conceptual perception assess-
ment, it is worth including patient and caregiver 
interviews to map the needs of the most important 
stakeholders of COPD care in Hungary. This cur-
rent study evaluated the importance of pharma-
cist care and the educational opportunities in the 
community pharmacy setting. It is important to 
note that patients originally did not associate lung 
problems with the pharmacists’ relevant knowl-
edge, though confidence was built up once they 
realized that their doubts were correctly ad-
dressed. 
In order to keep up with this spirit and to build 
the educators’ reputation in the project, we identi-
fied the following key benefits of employing a 
pharmacist in the project, along with [19]: 
1. primary prevention: campaigns, lifestyle coun-
seling, awareness raising; 
2. early diagnosis; 
3. management and ongoing support: pharmacist 
care, information on inhalation device use, dis-
ease outlook, dosage, self-management of the 
disease; 
4. overview and follow-up: monitoring adherence 
Figure 1 Major patient perceptions & attitudes and their implications for the development of education content
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and device use. This connects to the content of 
the community pharmacy pillar of our educa-
tion, and we considered these points to define 
the potential role of the pharmacist in our edu-
cation project. 
An important methodological point is high-
lighted: due to the heterogeneity of the studies, it 
is very hard to set up the optimal education, based 
on the publications reviewed, but it may be tailor-
made [20]. Finding the right balance between 
fixed content to keep measurements intercompa-
rable is a methodological prerequisite, whilst per-
sonalization seems to bring the most benefits to 
the patient. 
Taking the matter of standardization of educa-
tion content to a national level, data providers in 
Germany present such diversity that prefer not to 
compare [21]. The study confirms that these educa-
tion projects should be either aligned individually 
or require a higher level of coordination for initia-
tion. The most common errors that were found in 
46 of the 95 programs are as follows: evaluation of 
program success, inadequate transparency of cost 
data and the lack of the same in quality of life in-
terventions. It seems clear that success rates should 
be defined, although there are no consensus or an 
established method [22]. A prerequisite for the 
achievement of success indicators is that the pa-
tient is actively involved in the therapeutic process 
and has an individual action plan for the self-man-
agement of the disease [23]. Although very softly, 
[24, 25] also affirm that a caring environment, nice 
and competent words initiate the self-management 
process in the COPD patient. That is why we con-
sidered it supremely important along this study to 
keep patients motivated, especially by providing 
answers to all additional questions, once the ses-
sions were over, and the education with fixed con-
tent was delivered. 
A holistic summary of patient education oppor-
tunities [26] include printed brochures, recorded 
videos and audio-visual materials, self-education, 
self-monitoring, self-directed therapy, patient in-
volvement in therapy, patient interviews on side ef-
fects, organization of self-help and therapy groups, 
telemedicine, computer and internet patient infor-
mation, targeted interventions to improve health 
literacy in disadvantaged groups, and targeted 
media campaigns. The methods mentioned here 
depict another process: media and telemedicine 
should be the future direction, though currently 
we have not identified this need from our patients, 
apparently it would have been a disadvantage at 
this phase. Currently, we applied the methods in 
italics, and focused on the major benefit of the ed-
ucation sessions highlighted by the interview sub-
jects, which is, personal care and assistance 
throughout the project. 
A Canadian patient education project [27] cov-
ered adherence, inhalation techniques, health-re-
lated quality of life, and the use of health resourc-
es such as drug therapy and COPD exacerbations. 
Content included explanation of the current thera-
py, dosage, administration, patient expectations, 
duration of therapy, and potential outcomes, and 
follow-ups and improved inhaler use. By the 
“teach it back” strategy, understanding the com-
ponents of adherence caused by a lack of knowl-
edge and the patient’s perceptions of the disease 
have helped to enhance adherence. The “teach it 
back” strategy that is also vastly recommended by 
our interviews, patients appreciated when their 
opinion was considered and they were included 
in the sessions by embracing their true self and at-
titudes. 
An analog of this study [28] examined COPD 
self-management on n=176 patients, with the fol-
lowing education content: COPD status, medica-
tion, and respiratory training. Education should 
be structured to ensure that the measurements are 
inter-comparable. The education should consider 
the patients’ capabilities, so that the content can be 
acquired, and it has cost-effective long-term ef-
fects: less frequent exacerbations result in de-
creased use of healthcare resources [29].
The Belgian PHARMACOP study [30] shares 
the methodology of [31] and they are very similar 
to the final study design of our investigations. Al-
together, n = 734 patients were enrolled and fol-
lowed for 3 months. Adherence to maintenance 
therapy and the use of inhalation devices were the 
focus of the study, and education was provided to 
patients at baseline and after 1 month. Both vari-
ables were significantly better in the intervention 
group, and a significantly lower number of hospi-
talizations were reported. Using the in-depth in-
terview method, n=173 patients were reported 
that the absence of depression, comorbidities, and 
patient perception of the disease have a much 
greater impact on adherence than demographics 
or disease severity [28]. 
A major limitation for the first sight is the num-
bers of patients included in the study. In the set-
ting of Göd, this means 7% inclusion of the whole 
population. In order to achieve the same power of 
significance, we would need to include 35,000 pa-
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tients for Hungary, considering 500,000 COPD pa-
tients in the country [5]. Consequently, this aspect 
is considered as a relative limitation; however, it is 
an obstacle of the general applicability of our con-
clusions. 
6. Conclusions and caveats
We have developed an education content for 
COPD patients based on the input from patients 
from the community pharmacy. The education 
programme should reinforce physical activities, 
tailor-made to the current condition of the patient; 
furthermore, breathing techniques should be in-
corporated to avoid the abrupt appearance of 
breathlessness. Our relatively small sample dem-
onstrated such a diversity (like the ladies’ interest 
in alternative methods) that corresponds with pa-
tient beliefs described in the literature. 
Patient interviews vastly reveal the missing 
concepts, lack of pragmatic knowledge and (non)-
adherence data that should be tackled by in our 
education programme. A patient education proj-
ect was piloted in the community setting, and we 
will do our best to ensure the scientific support to 
its continuation (hopefully this means that re-
search objective III will continue on the long-term 
in Göd). Furthermore, this study has the benefit to 
envision the three key intervention areas that 
should be targeted by an education programme.
1. A relatively small number of COPD patients 
prefers the pharmacy to get education; howev-
er, those who come indeed, are motivated. Pa-
tients get used to COPD, and they accept “that 
this comes by age”, “I cannot do this”, though 
all of them mentioned an activity they still wish 
to pursue. 
2. Active listening to patient needs is an effective 
way to reveal important insight [11]. Namely, 
asking semi-structured questions; and permit-
ting them to talk about their issues helped us 
create the guidelines for such content they can 
benefit. Recording patients’ words and phrases 
also helps us to put together an easy-to-under-
stand material with catchy content. There is a 
need to expand the project, since once the pa-
tients decided to open up, they share all their 
experience; furthermore, these patient clubs are 
also in favour of their social inclusion and pro-
vide an opportunity to meet their peers. 
3. Research objectives I and II have been also met, 
and our findings are summarised in Figure 2. 
This table also seeks to incorporate the patient 
insight to an ideal education content. Since the 
project was well accepted, a local epitome has 
been created in the Inczeffy Pharmacy. 
4. It should be noted that the generalizability of 
our results is limited due to the small amount 
of patients included in the study, though this 
number represents 7% of the total COPD popu-
lation of Göd. Consequently, our results can be 
primarily applied in similar setting of towns or 
smaller cities. 
5. These results imply for the further development 
of research, that COPD patients prefer to take 
part in education more in the pulmonology out-
Figure 2 Elements of the suggested education content by COPD patients
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patient centre setting than the pharmacy. In or-
der to meet this need, a larger number of pa-
tients were recruited from the latter setting. 
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